Compare Agilent Technologies Inc (A) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs BioNano Genomics Inc — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.22B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Agilent Technologies Inc is far larger — about 3090.8× BioNano Genomics Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| A | BNGO | |
|---|---|---|
Market Cap | $42.22B | $13.66M |
Sector | Health | Health |
52-Week High | $157.20 | $4.92 |
52-Week Low | $110.24 | $1.06 |
Enterprise Value | $43.77B | $16.26M |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
